BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Harb H, Chatila TA. Mechanisms of Dupilumab. Clin Exp Allergy 2020;50:5-14. [PMID: 31505066 DOI: 10.1111/cea.13491] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 11.7] [Reference Citation Analysis]
Number Citing Articles
1 Nettis E, Brussino L, Patella V, Bonzano L, Detoraki A, Di Leo E, Sirufo MM, Caruso C, Lodi Rizzini F, Conte M, Yacoub MR, Triggiani M, Ridolo E, Macchia L, Rolla G, Brancaccio R, De Paulis A, Spadaro G, Di Bona D, D'Uggento AM, Ginaldi L, Gaeta F, Nucera E, Jaubashi K, Villalta D, Dagna L, Ciotta D, Pucciarini F, Bagnasco D, Celi G, Chieco Bianchi F, Cosmi L, Costantino MT, Crivellaro MA, D'Alò S, Del Biondo P, Del Giacco S, Di Gioacchino M, Di Pietro L, Favero E, Gangemi S, Guarnieri G, Heffler E, Leto Barone MS, Lombardo C, Losa F, Matucci A, Minciullo PL, Parronchi P, Passalacqua G, Pucci S, Rossi O, Salvati L, Schiappoli M, Senna G, Vianello A, Vultaggio A, Baoran Y, Incorvaia C, Canonica GW. Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life. Clin Mol Allergy 2022;20:6. [PMID: 35590407 DOI: 10.1186/s12948-022-00171-2] [Reference Citation Analysis]
2 Ellebrecht CT, Maseda D, Payne AS. Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways. J Invest Dermatol 2021:S0022-202X(21)02221-1. [PMID: 34756581 DOI: 10.1016/j.jid.2021.04.040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Fourzali K, Golpanian RS, Yosipovitch G. Dupilumab use in atopic dermatitis and beyond in skin diseases. Immunotherapy 2020;12:1221-35. [PMID: 32892674 DOI: 10.2217/imt-2020-0175] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
4 Kim HS, Yeung J. Psoriasis appearing after dupilumab therapy in atopic dermatitis: A case report. SAGE Open Med Case Rep 2020;8:2050313X20940458. [PMID: 32699634 DOI: 10.1177/2050313X20940458] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
5 Wan H, Yang H, Wei M, Chen W. Polyinosinic:polycytidylic acid aggravates calcipotriol-induced atopic dermatitis-like skin lesions in mice by increasing the expression of thymic stromal lymphopoietin. Ann Transl Med 2022;10:209. [PMID: 35280398 DOI: 10.21037/atm-22-282] [Reference Citation Analysis]
6 Nur Husna SM, Md Shukri N, Mohd Ashari NS, Wong KK. IL-4/IL-13 axis as therapeutic targets in allergic rhinitis and asthma. PeerJ 2022;10:e13444. [DOI: 10.7717/peerj.13444] [Reference Citation Analysis]
7 Pelaia C, Lombardo N, Busceti MT, Piazzetta G, Crimi C, Calabrese C, Vatrella A, Pelaia G. Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis. J Asthma Allergy 2021;14:1165-72. [PMID: 34594115 DOI: 10.2147/JAA.S328988] [Reference Citation Analysis]
8 Boyle RJ, Shamji MH. Developments in the field of allergy in 2020 through the eyes of Clinical and Experimental Allergy. Clin Exp Allergy 2021. [PMID: 34750898 DOI: 10.1111/cea.14046] [Reference Citation Analysis]
9 Moshirfar M, Seitz T, Ply B, Ronquillo YC, Hoopes PC. Corneal Refractive Surgery Considerations in Patients on Dupilumab. J Clin Med 2022;11:3273. [PMID: 35743344 DOI: 10.3390/jcm11123273] [Reference Citation Analysis]
10 van der Veer T, Dallinga MA, van der Valk JPM, Kappen JH, In 't Veen JCCM, van der Eerden MM, Braunstahl GJ. Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab. Clin Transl Allergy 2021;11:e12081. [PMID: 34962725 DOI: 10.1002/clt2.12081] [Reference Citation Analysis]
11 Nakano N, Kitaura J. Mucosal Mast Cells as Key Effector Cells in Food Allergies. Cells 2022;11:329. [DOI: 10.3390/cells11030329] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Castagnoli R, Licari A, Brambilla I, Tosca M, Ciprandi G, Marseglia GL. An update on the role of chronic rhinosinusitis with nasal polyps as a co-morbidity in severe asthma. Expert Rev Respir Med 2020;14:1197-205. [PMID: 32875924 DOI: 10.1080/17476348.2020.1812388] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
13 Alsaffar RM, Alkholifi FK. Exploring the efficacy and contribution of Dupilumab in asthma management. Mol Immunol 2022;146:9-17. [PMID: 35397375 DOI: 10.1016/j.molimm.2022.03.119] [Reference Citation Analysis]
14 Pellefigues C, Naidoo K, Mehta P, Schmidt AJ, Jagot F, Roussel E, Cait A, Yumnam B, Chappell S, Meijlink K, Camberis M, Jiang JX, Painter G, Filbey K, Uluçkan Ö, Gasser O, Le Gros G. Basophils promote barrier dysfunction and resolution in the atopic skin. J Allergy Clin Immunol 2021;148:799-812.e10. [PMID: 33662369 DOI: 10.1016/j.jaci.2021.02.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Mennini M, Di Nardo G, Fiocchi AG. Atopic dermatitis: time for tailored therapy. The Lancet 2022;400:252-3. [DOI: 10.1016/s0140-6736(22)01331-9] [Reference Citation Analysis]
16 Abdel Aziz N, Musaigwa F, Mosala P, Berkiks I, Brombacher F. Type 2 immunity: a two-edged sword in schistosomiasis immunopathology. Trends Immunol 2022:S1471-4906(22)00121-1. [PMID: 35835714 DOI: 10.1016/j.it.2022.06.005] [Reference Citation Analysis]
17 Rutherford M, Tran M, Salazar L, Iqbal F, Mazharuddin A, Camarena J. An Uncharacteristic Presentation of Evans Syndrome Following Treatment With Dupilumab. Cureus 2021;13:e16658. [PMID: 34462689 DOI: 10.7759/cureus.16658] [Reference Citation Analysis]
18 Licata G, Buononato D, Calabrese G, Gambardella A, Briatico G, Pagliuca F, Argenziano G. A case of Hailey-Hailey disease successfully treated with dupilumab. Int J Dermatol 2022. [PMID: 35766384 DOI: 10.1111/ijd.16322] [Reference Citation Analysis]
19 Newsom M, Bashyam AM, Balogh EA, Feldman SR, Strowd LC. New and Emerging Systemic Treatments for Atopic Dermatitis. Drugs 2020;80:1041-52. [PMID: 32519223 DOI: 10.1007/s40265-020-01335-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
20 Müller S, Bieber T, Ständer S. Therapeutic potential of biologics in prurigo nodularis. Expert Opin Biol Ther 2021;:1-12. [PMID: 34289753 DOI: 10.1080/14712598.2021.1958777] [Reference Citation Analysis]
21 Wang Y, Jorizzo J. Difference in the rate of ocular adverse events with dupilumab between asthma and atopic dermatitis patients. Int J Dermatol 2021;60:e382. [PMID: 33715168 DOI: 10.1111/ijd.15524] [Reference Citation Analysis]
22 Ferrucci S, Romagnuolo M, Angileri L, Berti E, Tavecchio S. Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports. J Eur Acad Dermatol Venereol 2020;34:e303-4. [PMID: 32330323 DOI: 10.1111/jdv.16527] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 14.5] [Reference Citation Analysis]
23 Abe Y, Suga Y, Fukushima K, Ohata H, Niitsu T, Nabeshima H, Nagahama Y, Kida H, Kumanogoh A. Advances and Challenges of Antibody Therapeutics for Severe Bronchial Asthma. Int J Mol Sci 2021;23:83. [PMID: 35008504 DOI: 10.3390/ijms23010083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Liu X, Wu W, Fang L, Liu Y, Chen W. TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis. Front Immunol 2022;13:922782. [DOI: 10.3389/fimmu.2022.922782] [Reference Citation Analysis]
25 Han X, Krempski JW, Nadeau K. Advances and novel developments in mechanisms of allergic inflammation. Allergy 2020;75:3100-11. [PMID: 33068299 DOI: 10.1111/all.14632] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 13.0] [Reference Citation Analysis]
26 Conde E, Bertrand R, Balbino B, Bonnefoy J, Stackowicz J, Caillot N, Colaone F, Hamdi S, Houmadi R, Loste A, Kamphuis JBJ, Huetz F, Guilleminault L, Gaudenzio N, Mougel A, Hardy D, Snouwaert JN, Koller BH, Serra V, Bruhns P, Grouard-Vogel G, Reber LL. Dual vaccination against IL-4 and IL-13 protects against chronic allergic asthma in mice. Nat Commun 2021;12:2574. [PMID: 33976140 DOI: 10.1038/s41467-021-22834-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Tubau C, Puig L. Therapeutic targeting of the IL-13 pathway in skin inflammation. Expert Rev Clin Immunol 2021;17:15-25. [PMID: 33275064 DOI: 10.1080/1744666X.2020.1858802] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Guan J, Li Y, Lu F, Feng J. Adipose-derived stem cells ameliorate atopic dermatitis by suppressing the IL-17 expression of Th17 cells in an ovalbumin-induced mouse model. Stem Cell Res Ther 2022;13:98. [PMID: 35255962 DOI: 10.1186/s13287-022-02774-7] [Reference Citation Analysis]
29 Fiocchi A, Vickery BP, Wood RA. The use of biologics in food allergy. Clin Exp Allergy 2021;51:1006-18. [PMID: 33966304 DOI: 10.1111/cea.13897] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Simonetti O, Radi G, Diotallevi F, Molinelli E, Rizzetto G, Offidani A. Prevention of conjunctivitis in patients with atopic dermatitis undergoing treatment with dupilumab: an Italian single-centre experience. Clin Exp Dermatol 2021;46:939-40. [PMID: 33576497 DOI: 10.1111/ced.14611] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Dai X, Utsunomiya R, Shiraishi K, Mori H, Muto J, Murakami M, Sayama K. Nuclear IL-33 Plays an Important Role in the Suppression of FLG, LOR, Keratin 1, and Keratin 10 by IL-4 and IL-13 in Human Keratinocytes. J Invest Dermatol 2021;141:2646-2655.e6. [PMID: 33865911 DOI: 10.1016/j.jid.2021.04.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
32 Porcaro F, Ullmann N, Allegorico A, Di Marco A, Cutrera R. Difficult and Severe Asthma in Children. Children (Basel) 2020;7:E286. [PMID: 33322016 DOI: 10.3390/children7120286] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Gao X, Leung TF, Wong GW, Ko WH, Cai M, He EJ, Chu IM, Tsang MS, Chan BC, Ling J, Fan X, Lu L, Lam CW, Wong CK. Meteorin-β/Meteorin like/IL-41 attenuates airway inflammation in house dust mite-induced allergic asthma. Cell Mol Immunol 2021. [PMID: 34848868 DOI: 10.1038/s41423-021-00803-8] [Reference Citation Analysis]
34 Lyly A, Laidlaw TM, Lundberg M. Pathomechanisms of AERD—Recent Advances. Front Allergy 2021;2:734733. [DOI: 10.3389/falgy.2021.734733] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Galli E, Fortina AB, Ricci G, Maiello N, Neri I, Baldo E, Berti I, Bonamonte D, Capra L, Carboni E, Carello R, Caroppo F, Cavagni G, Chinellato I, Cipriani F, Comberiati P, Diociaiuti A, Di Lernia V, Duse M, Filippeschi C, Giannetti A, Giovannini M, Licari A, Marseglia GL, Pace M, Patrizi A, Pajno GB, Peroni D, Villani A, Eichenfield L. Narrative review on the management of moderate-severe atopic dermatitis in pediatric age of the Italian Society of Pediatric Allergology and Immunology (SIAIP), of the Italian Society of Pediatric Dermatology (SIDerP) and of the Italian Society of Pediatrics (SIP). Ital J Pediatr 2022;48:95. [PMID: 35701810 DOI: 10.1186/s13052-022-01278-7] [Reference Citation Analysis]
36 Roberts G. Real-life data. Clin Exp Allergy 2020;50:764-5. [PMID: 32597534 DOI: 10.1111/cea.13684] [Reference Citation Analysis]
37 Passanisi S, Caminiti L, Zirilli G, Lombardo F, Crisafulli G, Aversa T, Pajno GB. Biologics in food allergy: up-to-date. Expert Opin Biol Ther 2021;:1-9. [PMID: 33733975 DOI: 10.1080/14712598.2021.1904888] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Morris J, Olonisakin TF, Moore JA, Phan B, Parker DM, Uribe BA, Barel SJ, Bowers EMR, Buchheit KM, Laidlaw TM, Lee SE. Inhibiting the type 2 inflammatory pathway with dupilumab is associated with an increase in interleukin-4 and interleukin-18 production. Int Forum Allergy Rhinol 2022. [PMID: 35394682 DOI: 10.1002/alr.23003] [Reference Citation Analysis]
39 Pellefigues C. IgE Autoreactivity in Atopic Dermatitis: Paving the Road for Autoimmune Diseases? Antibodies (Basel) 2020;9:E47. [PMID: 32911788 DOI: 10.3390/antib9030047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
40 Aviv H, Herzinger T, Molin S. Skin Barrier Dysfunction in Contact Dermatitis and Atopic Dermatitis-Treatment Implications. Curr Treat Options Allergy 2020;7:390-402. [DOI: 10.1007/s40521-020-00264-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Kim BK, Lee HS, Lee SY, Park HW. Different Biological Pathways Between Good and Poor Inhaled Corticosteroid Responses in Asthma. Front Med (Lausanne) 2021;8:652824. [PMID: 33816533 DOI: 10.3389/fmed.2021.652824] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Wu Y, Song H. A Comparative and Comprehensive Review of Antibody Applications in the Treatment of Lung Disease. Life 2022;12:130. [DOI: 10.3390/life12010130] [Reference Citation Analysis]
43 Jin M, Watkins S, Larriba Y, Wallace C, St Croix C, Zhou X, Zhao J, Peddada S, Wenzel SE. Real-time imaging of asthmatic epithelial cells identifies migratory deficiencies under type-2 conditions. J Allergy Clin Immunol 2021:S0091-6749(21)01402-0. [PMID: 34547368 DOI: 10.1016/j.jaci.2021.08.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Kariyawasam HH. Chronic rhinosinusitis with nasal polyps: mechanistic insights from targeting IL-4 and IL-13 via IL-4Rα inhibition with dupilumab. Expert Rev Clin Immunol 2020;16:1115-25. [PMID: 33148074 DOI: 10.1080/1744666X.2021.1847083] [Reference Citation Analysis]
45 Nettis E, Masciopinto L, Di Leo E, De Candia N, Albanesi M, Di Bona D, Quaranta N, Macchia L. Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis. Clin Mol Allergy 2021;19:9. [PMID: 34134707 DOI: 10.1186/s12948-021-00144-x] [Reference Citation Analysis]
46 Yang X, Kambe N, Takimoto-ito R, Kabashima K. Advances in the pathophysiology of atopic dermatitis revealed by novel therapeutics and clinical trials. Pharmacology & Therapeutics 2021;224:107830. [DOI: 10.1016/j.pharmthera.2021.107830] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Brar KK, Lanser BJ, Schneider A, Nowak-wegrzyn A. Biologics for the Treatment of Food Allergies. Immunology and Allergy Clinics of North America 2020;40:575-91. [DOI: 10.1016/j.iac.2020.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Shibata Y, Sano S. Keratosis pilaris caused by dupilumab for the treatment of bronchial asthma. J Cutan Immunol Allergy 2021;4:82-5. [DOI: 10.1002/cia2.12172] [Reference Citation Analysis]
49 Yu D, Walker LSK, Liu Z, Linterman MA, Li Z. Targeting TFH cells in human diseases and vaccination: rationale and practice. Nat Immunol 2022. [PMID: 35817844 DOI: 10.1038/s41590-022-01253-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Tubau C, Puig L. IL-13 antagonists in the treatment of atopic dermatitis. Immunotherapy 2021;13:327-44. [PMID: 33430628 DOI: 10.2217/imt-2020-0253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Reji MA, Haque A, Goyal S, Krishnaswamy G. Dupilumab-induced ocular surface disease: a primer. BMJ Case Rep 2022;15:e249019. [PMID: 35414583 DOI: 10.1136/bcr-2022-249019] [Reference Citation Analysis]
52 Pelaia C, Pelaia G, Crimi C, Maglio A, Armentaro G, Calabrese C, Sciacqua A, Gallelli L, Vatrella A. Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13. Vaccines (Basel) 2022;10:974. [PMID: 35746582 DOI: 10.3390/vaccines10060974] [Reference Citation Analysis]
53 Cao P, Xu W, Zhang L. Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review. Front Immunol 2022;13:928621. [DOI: 10.3389/fimmu.2022.928621] [Reference Citation Analysis]
54 Mitsias DI, Xepapadaki P, Makris M, Papadopoulos NG. Immunotherapy in allergic diseases - improved understanding and innovation for enhanced effectiveness. Curr Opin Immunol 2020;66:1-8. [PMID: 32272340 DOI: 10.1016/j.coi.2020.02.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
55 Caminati M, Olivieri B, Dama A, Micheletto C, Paggiaro P, Pinter P, Senna G, Schiappoli M. Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management. Expert Rev Respir Med 2022;:1-9. [PMID: 35703018 DOI: 10.1080/17476348.2022.2090342] [Reference Citation Analysis]
56 Licari A, Castagnoli R, Marseglia A, Olivero F, Votto M, Ciprandi G, Marseglia GL. Dupilumab to Treat Type 2 Inflammatory Diseases in Children and Adolescents. Paediatr Drugs 2020;22:295-310. [PMID: 32157553 DOI: 10.1007/s40272-020-00387-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
57 Pelaia C, Heffler E, Crimi C, Maglio A, Vatrella A, Pelaia G, Canonica GW. Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets. Front Pharmacol 2022;13:851940. [PMID: 35350765 DOI: 10.3389/fphar.2022.851940] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
58 Criado PR, Pincelli TP, Criado RFJ. Dupilumab as a useful treatment option for prurigo nodularis in an elderly patient with atopic diathesis. Int J Dermatol 2020;59:e358-61. [PMID: 32562425 DOI: 10.1111/ijd.14994] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
59 Wu D, Daniel BS, Lai AJX, Wong N, Lim DKA, Murrell DF, Lim BXH, Mehta JS, Lim CHL. Dupilumab-associated ocular manifestations: A review of clinical presentations and management. Surv Ophthalmol 2022:S0039-6257(22)00030-3. [PMID: 35181280 DOI: 10.1016/j.survophthal.2022.02.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Lourenço LO, Ribeiro AM, Lopes FDTQDS, Tibério IFLC, Tavares-de-Lima W, Prado CM. Different Phenotypes in Asthma: Clinical Findings and Experimental Animal Models. Clin Rev Allergy Immunol 2021. [PMID: 34542807 DOI: 10.1007/s12016-021-08894-x] [Reference Citation Analysis]
61 Albuhairi S, Rachid R. Biologics and Novel Therapies for Food Allergy. Immunol Allergy Clin North Am 2021;41:271-83. [PMID: 33863483 DOI: 10.1016/j.iac.2021.01.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Pelaia C, Crimi C, Vatrella A, Tinello C, Terracciano R, Pelaia G. Molecular Targets for Biological Therapies of Severe Asthma. Front Immunol 2020;11:603312. [PMID: 33329598 DOI: 10.3389/fimmu.2020.603312] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
63 Pelaia C, Pelaia G, Crimi C, Maglio A, Stanziola AA, Calabrese C, Terracciano R, Longhini F, Vatrella A. Novel Biological Therapies for Severe Asthma Endotypes. Biomedicines 2022;10:1064. [DOI: 10.3390/biomedicines10051064] [Reference Citation Analysis]
64 Reihman AE, Holguin F, Sharma S. Management of Severe Asthma Beyond the Guidelines. Curr Allergy Asthma Rep 2020;20:47. [PMID: 32548649 DOI: 10.1007/s11882-020-00940-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]